The AI Cardiometabolic Research Intelligence agent — heart, vessels & metabolism, bench to real-world.
A scientific research agent (not a chatbot, not a diagnostic tool) that discovers, connects, analyses, challenges and synthesises cardiometabolic knowledge from authorized literature, databases, datasets and enterprise tools — to help you understand what is known, what is unknown, what may be true, what has failed and what to test next.
Twelve deeply-connected knowledge domains spanning the research lifecycle.
Heart failure, coronary & atherosclerotic disease, hypertension, arrhythmia, dyslipidemia, obesity, MASLD/MASH, insulin resistance, metabolic syndrome and cardio-renal-metabolic overlap.
Cardiomyocyte & vascular biology, lipid & lipoprotein metabolism, hepatic/adipose/muscle crosstalk, RAAS & natriuretic systems, fibrosis, inflammation and mitochondrial energetics.
Genomics (GWAS, Mendelian randomization, PRS), transcriptomics, proteomics, lipidomics/metabolomics and microbiome — connected DNA → metabolite → cell → phenotype.
LDL/ApoB, Lp(a), triglycerides, remnant cholesterol, glucose & incretin biology, bile acids and NAFLD/MASH mechanisms — mechanism → biomarker → target → therapy → outcome.
Human genetic, causal, animal, cellular and multi-omics evidence for cardiometabolic targets — with tractability, safety, existing pharmacology and prior failures clearly separated.
Small molecules, biologics, peptides (GLP-1/GIP/amylin), RNA therapeutics (siRNA, ASO), gene therapies and repurposing across the discovery-to-development cascade.
Diagnostic, prognostic, predictive and PD biomarkers across omics, cardiac imaging, CGM and wearables — with performance, validation and clinical-utility context.
Design, population, endpoints (MACE, HF hospitalization, LDL/HbA1c), biomarkers, comparators, results and adverse events — surfacing failed hypotheses and design opportunities.
Cardiac devices, safety signals, recalls, regulatory actions, adherence, persistence and real-world effectiveness — distinguishing a signal from confirmed causality.
Survival, regression, Mendelian randomization, causal inference, multi-omics integration and predictive risk modelling on authorized cardiometabolic datasets.
Reasons across Disease ↔ Gene ↔ Variant ↔ Protein ↔ Metabolite ↔ Cell ↔ Biomarker ↔ Target ↔ Drug ↔ Trial ↔ Outcome, with every claim traceable to primary sources.
Finds conflicting findings, unexplained mechanisms, missing biomarkers, poorly-validated targets and reproducibility gaps — then frames testable hypotheses and experiments.
Surface novel, testable research directions and drug-repurposing leads across the whole ecosystem — not a single paper.
Integrate literature, omics, trials and real-world data into one traceable evidence graph so hidden connections become visible.
A built-in scientific critic tests for confounding, batch effects, power, publication bias, replication and prior failures.
Research questions, proposals, protocols, SAPs, reviews and manuscript scaffolds — never fabricating data, patients, stats or citations.
Statements are tagged so you always know their standing — and confidence is stated, never inflated. Citations, DOIs, PMIDs, dataset and trial IDs are drawn from primary sources; if a source can't be verified it says so. Cardiometabolic Genius is a research-intelligence system, not a substitute for a physician — it does not diagnose or treat individuals.
We use cookies to run Anxya Health and improve your experience. Choose how we may use them. Read our Cookie Policy, Privacy Policy and Terms.